Positions for Ophthotech Corp (NASDAQ:OPHT)

“Big money sentiment for Ophthotech Corp (NASDAQ:OPHT) in Q3 2018 decreased to 0.79, according to Securities and Exchange Commission filings. That’s down -0.38, from 2018Q2’s 1.17. 22 hedge funds opened new and increased positions, while 28 cut down and sold equity positions in Ophthotech Corp so the sentiment dived. These funds own 15.12 million shares, that’s down from 17.21 million shares in 2018Q2. Funds holding Ophthotech Corp in top 10 was flat from 0 to 0 for the same number . 9 Investors Sold All; 19 Reduced Holdings; 12 increased holdings while 10 hedge funds bought holdings.

Largest Ophthotech Corp Shareholders

Sabby Management Llc owns 1.62 million shares in Ophthotech Corp as of Q3 2018. Ophthotech Corp’s shareholder Spark Investment Management Llc owns 394,000 shares as of Q3 2018. Furthermore, Thompson Davis & Co. Inc. reported 7,843 shares in Ophthotech Corp equivalent to 0.04% of its US equity exposure. Acadian Asset Management Llc revealed 1.22 million shares position in Ophthotech Corp. The Pennsylvania-based fund Ajo Lp looks positive on Ophthotech Corp, having 1.09 million shares.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye.The firm is valued at $57.36 million. The Company’s principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration .Currently it has negative earnings. The firm is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD.

OPHT is reaching $1.39 during the last trading session, after decreased 0.71%.Currently Ophthotech Corporation is downtrending after 46.42% change in last January 13, 2018. OPHT has also 95,988 shares volume. OPHT underperformed the S&P500 by 46.42%.

Ophthotech Corporation (NASDAQ:OPHT)’s quarterly earnings will be published on February, 26., as reported by RTT. Analysts forecast 42.31 % diference or $-0.37 from the $-0.26 EPS from 2018. Analysts at Wall Street see Ophthotech Corporation’s -9.76 % EPS growth compared to $-0.41 earnings per share for last quarter.

Moreover, Sabby Mngmt Llc has 0.49% invested in Ophthotech Corporation (NASDAQ:OPHT) for 1.62M shs. Jacobs Levy Equity Inc holds 0.01% or 238,747 shs in its capital. Bnp Paribas Arbitrage Sa has 0% invested in Ophthotech Corporation (NASDAQ:OPHT) for 60 shs. Royal National Bank & Trust Of Canada reported 2,293 shs stake. Grp Inc One Trading Lp invested 0% of its capital in Ophthotech Corporation (NASDAQ:OPHT). Ajo Lp, a Pennsylvania-based fund reported 1.09M shs. Endurance Wealth Management Inc reported 0% stake. State Bank Of Mellon Corp has 0% invested in Ophthotech Corporation (NASDAQ:OPHT) for 48,366 shs. Stratos Wealth Ptnrs Limited has 70 shs. 683,400 were accumulated by Renaissance Tech Ltd Llc. Us Natl Bank De holds 0% or 56,500 shs. Blackrock Incorporated holds 0% in Ophthotech Corporation (NASDAQ:OPHT) or 777,527 shs. California-based Wells Fargo Mn has invested 0% in Ophthotech Corporation (NASDAQ:OPHT). Vanguard Group Inc Inc stated it has 0% of its capital in Ophthotech Corporation (NASDAQ:OPHT). D E Shaw & holds 2.63M shs.

Ophthotech Corporation registered $10,340 net activity with 0 insider purchases and 4 selling transactions since January 2, 2019. On Friday, January 4 3,859 shs were sold by GUYER DAVID R, worth $5,017.

For more Ophthotech Corporation (NASDAQ:OPHT) news published briefly go to: Businesswire.com, Businesswire.com, Streetinsider.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Ophthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura® Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration – Business Wire” published on October 04, 2018, “Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration – Business Wire” on November 12, 2018, “Ophthotech Corp (OPHT) Appoints Calvin (Cal) W. Roberts MD to Board – StreetInsider.com” with a publish date: January 02, 2019, “Ophthotech inks gene therapy agreements for RP candidate; shares ahead 13% premarket – Seeking Alpha” and the last “Varian Medical Systems (VAR) Is Climbing After Q4 Report – Nasdaq” with publication date: October 24, 2018.

Ophthotech Corporation (NASDAQ:OPHT) Institutional Investors Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.




Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *